Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio

GlobeNewswire December 19, 2018

KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)

GlobeNewswire December 12, 2018

KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing

PR Newswire December 11, 2018

Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th

PR Newswire December 4, 2018

KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th

PR Newswire December 3, 2018

Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire November 21, 2018

KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

GlobeNewswire November 13, 2018

KemPharm, Inc. Reports Third Quarter 2018 Results

GlobeNewswire November 8, 2018

KemPharm to Report Third Quarter 2018 Results

GlobeNewswire November 1, 2018

KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®

GlobeNewswire October 30, 2018

KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting

GlobeNewswire October 24, 2018

KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications

GlobeNewswire October 23, 2018

KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape

GlobeNewswire October 11, 2018

KemPharm Announces Pricing of Public Offering of Common Stock

GlobeNewswire October 5, 2018

KemPharm Announces Proposed Public Offering of Common Stock

GlobeNewswire October 4, 2018

KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape

GlobeNewswire October 3, 2018

KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug

GlobeNewswire September 17, 2018

KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug

GlobeNewswire September 11, 2018

KemPharm to Present at Two Healthcare Investor Conferences During September 2018

GlobeNewswire September 5, 2018

KemPharm, Inc. Reports Second Quarter 2018 Results

GlobeNewswire August 9, 2018